This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Omeros Hires Michael K. Inouye To Lead Commercial Operations

SEATTLE, Oct. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company with marketing applications for its lead product OMS302 for use during lens replacement surgery currently under review in both the US and Europe, today announced the appointment of Michael K. Inouye as vice president, commercial operations.

Mr. Inouye has over 20 years of management experience in the pharmaceutical industry.  His experience includes positions as senior vice president, corporate and commercial development for Pharmacyclics, and senior vice president, commercial operations at Telik. Prior to that, he was senior vice president of commercial operations at Gilead Sciences from 1995 to 2004 where he developed and led the worldwide commercial organization through four product launches while Gilead grew from a research and development organization to an international commercial company.  Before Gilead, he was vice president sales and marketing at InSite Vision, an ophthalmic drug delivery company.  Prior to his biopharma experience he held management positions of increasing responsibility in sales, marketing and business development over 13 years at Merck US Human Health. From 2005 through its acquisition by Gilead in 2012, Mr. Inouye served on the board of directors of Pharmasset.

"We are very pleased that Mike has joined Omeros," said Gregory A. Demopulos, M.D., Omeros' chairman and chief executive officer. "With his deep expertise in building commercial organizations and his proven track record of successful drug-product launches, Mike is an important part of our team as we prepare for and execute the 2014 planned launch of OMS302. Given his breadth of experience, I expect that Mike will also play a key role in advancing the rest of our pipeline toward commercialization."

"The strength of Omeros' management team and the potential of its product pipeline are impressive," stated Mr. Inouye.  "OMS302 represents the beginning of Omeros' transition from an R&D organization to a commercial company, and I am honored to play a role in this phase of corporate growth."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs